M. Schroter et al., GB virus C hepatitis G virus infection in hemodialysis patients: Determination of seroprevalence by a four-antigen recombinant immunoblot assay, J MED VIROL, 57(3), 1999, pp. 230-234
GB Virus C/Hepatitis G Virus (GBV-C/HGV) was identified recently and only t
wo assays, consisting of a single recombinant protein, have been described
for determination of the seroprevalence of this virus. An immunoblot assay
was devised, which contains four recombinant GBV-C/HGV proteins. In this st
udy, serum samples from 154 patients on maintenance hemodialysis were exami
ned to assess the rate of seroreactivity against GBV-C/HGV. All sera were t
ested for the presence of antibodies by an in-house recombinant immunoblot
assay, for GBV-C/HGV viremia by RT-PCR, and for HCV infection by PCR and by
serological assays. Antibody reactivity against GBV-C/HGV was detected in
20.8% (n = 32) and viremia was found in 6.5% (n = 10) of the patients. In n
o case were viremia and GBV-C/HGV antibodies detected in parallel. HCV infe
ction was observed in 15.6% (n = 24) by RT-PCR. In 20 of these patients, HC
V antibodies were detected by enzyme immune assay (EIA) and immunoblot assa
y. However, four of the HCV PCR-positive patients were negative by both ser
ological tests. Only two patients were viremic for GBV-C/HGV and HCV in par
allel. It is concluded that antibody reactivity against GBV-C/HGV is common
among patients on maintenance hemodialysis. In contrast to HCV, parallel o
ccurrence of GBV-C/HGV vi rem ia a nd GBV-C/HGV seroreactivity was not obse
rved. This suggests that GBV-C/HGV infection might be self-limiting. J. Med
. Virol. 57:230-234, 1999. (C) 1999 Wiley-Liss, Inc.